Spinal Muscular Atrophy

December 16th 2024

The combination of Spinraza and Zolgensma could improve clinical outcomes in infants with spinal muscular atrophy without added risks.

December 11th 2024

Preserving the ability to swallow reduces the need for invasive interventions and lowers the risk of life-threatening complications such as aspiration pneumonia.

December 4th 2024

In a meta-analysis of 57 studies, Zolgensma achieved a 95% survival rate and reduced the number of patients requiring ventilatory support.

November 18th 2024

The study drew on data from the RESTORE registry for 34 patients with tracheostomies who received Zolgensma (onasemnogene abeparvovec).